shelf(0)

No. 030 · Mind · Nootropic Peptide

Cerebrolysin

FPF-1070Cerebroprotein hydrolysate

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA — not listed
Compare Cite
Fingerprint no sequence
Cerebrolysin (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Multiple RCTs in stroke and dementia (e.g. CARS trial, Stroke 2016; vascular dementia trial, 2011); nationally authorised in several countries but never FDA-approved or centrally EMA-authorised.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Intramuscular, Intravenous Routes used in published research
FDA
Not approved
Other approvals
  • Nationally authorised in several European countries (e.g. Romania, authorisation 4804/2012) and elsewhere; not centrally authorised by the EMA
WADA
Not on the Prohibited List
03

Overview

A peptide preparation produced by enzymatic hydrolysis of porcine brain proteins, containing low-molecular-weight peptides and amino acids. It is authorised as a medicine in several countries for stroke, traumatic brain injury, and dementia, but not in the US or via the EMA.

Research status Nationally authorised in several countries (e.g. Romania) but not FDA-approved or centrally EMA-authorised; multiple randomized controlled trials published

04

Mechanism

Cerebrolysin is an enzymatic hydrolysate of porcine brain proteins containing low-molecular-weight peptides and free amino acids. Its peptides are proposed to mimic the activity of endogenous neurotrophic factors (BDNF, NGF, GDNF), supporting neuronal survival and synaptic plasticity, although its exact active components are not defined.

05

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Neurotrophic factor delivery to the brain
  • Studied for recovery after stroke or TBI
  • Enhanced neuroplasticity and synaptogenesis
  • Reduced neurodegeneration in dementia models
06

Safety & unknowns

Multiple published RCTs; reported side effects include dizziness, headache, injection site pain, and insomnia. Generally well-tolerated in clinical trials. Not FDA-approved in the US. Must be administered parenterally.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [1]

  1. Clinical trial 2011

    Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

    Guekht AB, Moessler H, Novak PH, et al. Journal of Stroke and Cerebrovascular Diseases

    In a 24-week randomized, double-blind, placebo-controlled multicenter trial in vascular dementia, adding Cerebrolysin improved cognitive (ADAS-cog+) and global (CIBIC+) outcomes and was well tolerated.

    [pubmed] [doi]

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Cerebrolysin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cerebrolysin/

$ cite --format=bibtex 
@misc{peptidemeta-cerebrolysin,
  title = {Cerebrolysin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/cerebrolysin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open